Real-World study checks Brigatinib's performance in lung cancer
NCT ID NCT05735327
First seen Apr 15, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This study follows 50 adults with ALK-positive non-small cell lung cancer who are taking brigatinib as their first treatment. Researchers want to see how long the cancer stays under control and how many patients respond to the drug. No new treatment is given; data is collected during regular hospital visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centrum Onkologii im.Prof. F. Lukaszczyka w Bydgoszczy
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
-
Centrum Pulmonologii i Torakochirurgii w Bystrej
Bystra, Slskie, 43-360, Poland
-
Dolnoslskie Centrum Onkologii, Pulmonologii i Hematologii
Wroclaw, Dolnoslskie, 53-413, Poland
-
Instytut Gruzlicy i Chorob Pluc
Warsaw, Masovian Voivodeship, 01-138, Poland
-
Krakowski Szpital Specjalistyczny im. Jana Pawla II w Krakowie
Krakow, Lesser Poland Voivodeship, 31-202, Poland
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, Panstwowy Instytut Badawczy
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie- Panstwowy Instytut Badawczy Oddzial w Krakowie
Krakow, Lesser Poland Voivodeship, 31-115, Poland
-
Podkarpackie Centrum Chorob Pluc
Rzeszów, Podkarpackie Voivodeship, 35-241, Poland
-
SPZOZ Uniwersytecki Szpital Kliniczny nr 2 im. Wojskowej Akademii Medycznej Uniwersytetu Medycznego w Lodzi Centralny Szpital Weteranow
Lodz, Łódź Voivodeship, 90-549, Poland
-
Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
Lublin, Lublin Voivodeship, 20-954, Poland
-
Szpital Kliniczny im. Heliodora Swiecickiego UM wPoznaniu.
Poznan, Greater Poland Voivodeship, 60-355, Poland
-
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
Poznan, Greater Poland Voivodeship, 60-569, Poland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brigatinib
What this could lead to
If successful, this study could confirm that brigatinib is effective in everyday clinical practice for ALK-positive lung cancer, supporting its continued use.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes 50 people and does not test a new treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.